Linked Life Data

1830029

Source:http://linkedlifedata.com/resource/pubmed/id/1830029

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1991-8-19
pubmed:abstractText
Human PBMCs from healthy donors were cultured with 100 U/ml rIL-2 for up to 5 weeks and tested at short and long activation times for the ability to mediate CD3 and CD16 targeted cytotoxicity using chemically cross-linked bispecific antibodies. At each period, LAK activity was augmented with the use of bispecific antibodies (BA), whereas interestingly enough, at later periods (4-5 weeks) when CD16 positive lymphocytes are not present by flow cytometry, CD16 targeted cytotoxicity was induced. We suspected the possibility of CD16 expression on activated T cells and have purified the T cell subpopulations to see the targeted cytotoxicity. Populations enriched for T cells by Percoll density centrifugation, treatment with anti-CD16 plus complement or sorting for CD5+ cells, were all able to mediate CD16 targeted cytotoxicity following activation with rIL-2. These data suggest that IL-2 activated T cells express CD16 in addition to CD3.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0165-2478
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
31-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Interleukin-2 activated T cells (T-LAK) express CD16 antigen and are triggered to target cell lysis by bispecific antibody.
pubmed:affiliation
Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan.
pubmed:publicationType
Journal Article, In Vitro